Table 3.
Association of 9 SNPs of the CCL5 and CCL5 signaling pathway with triple negative breast cancer risk.
| SNP | Gene | Genotype | Controls | Cases | Heterozygotesa | Homozygotesb | Per risk allele | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N = 538 | N = 196 | OR (95%CI) | P | OR (95%CI) | P | OR (95%CI) | P | |||
| rs2107538 | CCL5 | CC | 389 | 125 | 1.42 (0.99–2.03) | 0.055* | 2.26 (0.89–5.75) | 0.079* | 1.45 (1.07–1.95) | 0.015 |
| CT | 138 | 63 | ||||||||
| TT | 11 | 8 | ||||||||
| rs2280788 | CCL5 | GG | 535 | 192 | 4.98 (0.91–27.41) | 0.041* | 2.49 (0.05–125.72) | NS | 4.94 (0.9–27.07) | NS |
| GC | 3 | 4 | ||||||||
| CC | 0 | 0 | ||||||||
| rs2280789 | CCL5 | AA | 423 | 148 | 1.11 (0.75–1.65) | NS | 5.72 (1.04–31.53) | 0.024* | 1.254 (0.88–1.78) | NS |
| AG | 113 | 44 | ||||||||
| GG | 2 | 4 | ||||||||
| rs614367 | CCND1 | CC | 435 | 148 | 1.22 (0.81–1.83) | NS | 5.14 (1.49–17.82) | 0.004** | 1.48 (1.04–2.09) | 0.027 |
| CT | 99 | 41 | ||||||||
| TT | 4 | 7 | ||||||||
| rs704010 | ZMIZ1 | CC | 271 | 94 | 1.02 (0.72–1.44) | NS | 1.54 (0.88–2.69) | NS | 1.16 (0.9–1.49) | NS |
| CT | 224 | 79 | ||||||||
| TT | 43 | 23 | ||||||||
| rs1045485 | CASP8 | GG | 416 | 151 | 0.97 (0.64–1.46) | NS | 1.5 (0.55–4.13) | NS | 1.06 (0.75–1.5) | NS |
| GC | 111 | 39 | ||||||||
| CC | 11 | 6 | ||||||||
| rs1124933 | NOTCH2 | GG | 233 | 96 | 0.73 (0.51–1.03) | NS | 1 (0.64–1.57) | NS | 0.93 (0.73–1.19) | NS |
| GA | 241 | 72 | ||||||||
| AA | 64 | 28 | ||||||||
| rs1294255 | MAP3K21 | GG | 192 | 76 | 0.83 (0.72–1.19) | NS | 0.99 (0.63–1.56) | NS | 0.97 (0.77–1.23) | NS |
| GC | 245 | 80 | ||||||||
| CC | 101 | 40 | ||||||||
| rs1924587 | HS6ST3 | GG | 216 | 63 | 1.51 (1.05–2.17) | 0.025* | 1.13 (0.67–1.91) | NS | 1.15 (0.91–1.46) | NS |
| GC | 243 | 107 | ||||||||
| CC | 79 | 26 | ||||||||
CI, confidence interval; OR, odds ratio.
a
Heterozygotes compared to homozygotes of reference allele.
b
Homozygotes of risk allele compared to homozygotes of reference allele.
The chi-square test was used to determine whether significant differences (P-value) were observed when TNBC patient group was compared with control subjects. Significant P-values are in bold cases.
**
The association remains significant after age and menopausal status adjustment.
*
Not significant after age and menopausal status adjustment.